

**Table 2**

Prevalence of the Metabolically Healthy Phenotype and Number of Metabolic Syndrome Components as a Function of Age

Age, y (No.)	Men				Women			
	MH, %	1 component, %	2 components, %	3 components, %	MH, %	1 component, %	2 components, %	3 components, %
18-24 (M = 77, W = 318)	96.54	3.09	0.37	0	95.96	2.29	1.05	0.70
25-34 (M = 215, W = 1277)	81.05	14.01	4.06	0.88	87.09	6.52	2.89	3.50
35-44 (M = 276, W = 1652)	60.67	18.29	14.02	7.02	70.23	15.91	7.79	6.07
45-54 (M = 250, W = 1515)	40.39	23.75	19.19	16.67	35.70	29.18	19.70	15.42
55-64 (M = 255, W = 1131)	14.10	23.75	27.68	34.47	6.63	27.85	34.68	30.84
65-74 (M = 216, W = 1131)	12.25	17.10	34.69	35.96	4.40	18.25	33.89	43.46
Total (18-74) (M = 1289, W = 6683)	48.07	27.13	17.46	7.35	57.87	24.90	12.53	4.70
Chi-square = 510.68; <i>P</i> < .001				Chi-square = 569.71; <i>P</i> < .01				

M, men; MH, metabolically healthy; W, women.

comorbidity.<sup>6</sup> In both studies, the appearance of metabolic syndrome components in people with excess body weight increased sharply between the fourth and fifth decades of life.

Women generally have a greater interest than men in losing weight and are consequently more likely to attend a dietetic consultation. This tendency is reflected in the imbalance between the numbers of men and women in our series, which is a limitation of the study. Other limitations are the cross-sectional nature of the study and the sourcing of data from a single provider. The analysis of abdominal obesity is still in progress and will provide further information about the link between excess weight and the other metabolic syndrome components. Nonetheless, the preliminary results presented here provide an overview of the prevalence of metabolic syndrome components in Spanish people with overweight and obesity and support the hypothesis that apparently healthy obesity naturally progresses to cardiometabolic deterioration.

María Dolores Marrodán Serrano,<sup>a,b,\*</sup>

Jesús Román Martínez-Álvarez,<sup>a,c</sup> María Sánchez-Álvarez,<sup>a,b</sup>  
Noemí López-Ejeda,<sup>a,b</sup> Irene Alférez García,<sup>d</sup>  
and Antonio Villarino Marín<sup>a,c</sup>

<sup>a</sup>Grupo de Investigación EPINUT, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

<sup>b</sup>Departamento de Zoología y Antropología Física, Facultad de Biología, Universidad Complutense de Madrid, Madrid, Spain

<sup>c</sup>Sociedad Española de Dietética y Ciencias de la Alimentación (SEDCA), Madrid, Spain

<sup>d</sup>Laboratorios Arkopharma, Madrid, Spain

\* Corresponding author:

E-mail address: [marrodan@ucm.es](mailto:marrodan@ucm.es) (M.D. Marrodán Serrano).

Available online 13 January 2016

## REFERENCES

1. Acevedo P, López-Ejeda N, Alférez-García I, Martínez-Álvarez JR, Villarino A, Cabañas MD, et al. Body mass index through self-reported data and body image perception in Spanish adults attending dietary consultation. *Nutrition*. 2014;30:679–84.
2. World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects. 59th General Assembly (Seoul, Korea). [Accessed 1 February 2013]. Available at: <http://www.wma.net/es/30publications/10policias/b3/17c.pdf>
3. International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome. 2006. [Accessed 15 January 2015]. Available at: [http://www.idf.org/webdata/docs/IDF\\_Meta\\_def\\_final.pdf](http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf)
4. Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, Rodriguez-Artalejo F. Prevalence and determinants of metabolically healthy obesity in Spain. *Atherosclerosis*. 2013;231:152–7.
5. Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E, García-Fuentes E, Alamaraz MC, Colomo N, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. *J Clin Endocrinol Metab*. 2013;98:2318–25.
6. Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years. *J Am Coll Cardiol*. 2015;65:101–2.

<http://dx.doi.org/10.1016/j.rec.2015.09.021>

## Prognostic Value of the Residual SYNTAX Score in Octogenarian Patients With Non-ST-elevation Acute Coronary Syndrome



### Valor pronóstico de la puntuación SYNTAX residual en pacientes octogenarios con síndrome coronario agudo sin elevación del segmento ST

#### To the Editor,

Invasive treatment in high-risk patients with non-ST-elevation acute coronary syndrome (NSTEACS) has been shown to improve

their prognosis in terms of cardiovascular death and reinfarction.<sup>1</sup> The prevalence of multivessel disease in these patients stands at about 50% and experts agree that performing complete revascularization is beneficial in such patients.<sup>1</sup>

Patients older than 75 years are underrepresented in studies and account for up to 35% of the total.<sup>1</sup> Although these older patients benefit from invasive treatment,<sup>2</sup> only a small percentage undergo percutaneous coronary intervention (PCI) and/or complete revascularization compared with younger patients.<sup>1,2</sup>

We have observed a growing interest in residual disease burden after PCI. The residual SYnergy between PCI with TAXus and cardiac surgery (SYNTAX) score (rSS), described by Génereux et al,<sup>3</sup>

**Table**  
Baseline Characteristics and Variables During Admission by Residual SYNTAX Score

Variable	Overall n = 76	rSS < 8 n = 21	rSS 8-20 n = 37	rSS > 20 n = 18	P
Sex (women), %	57.9 (n=44)	57 (n=12)	62 (n=23)	50 (n=9)	.69
Age, y	84 ± 2.8	84.3 ± 2.9	84.05 ± 2.9	84.5 ± 2.6	.86
Hypertension, %	94.7 (n=72)	95.2 (n=20)	97.3 (n=36)	88.9 (n=16)	.42
Diabetes, %	42.1 (n=32)	42.9 (n=9)	37.8 (n=14)	50 (n=9)	.69
COPD, %	15.8 (n=12)	9.5 (n=2)	13.5 (n=5)	27.7 (n=5)	.25
PVD, %	26.3 (n=20)	19 (n=4)	21.6 (n=8)	44.4 (n=8)	.13
Previous CIHD, %	38.2 (n=29)	23.8 (n=5)	45.9 (n=17)	38.9 (n=7)	.24
Previous stroke, %	18.4 (n=14)	19 (n=4)	8 (n=3)	38.9 (n=7)	<b>.022</b>
LVEF, %	52.9 ± 9.8	53.8 ± 11.1	52.97 ± 10.2	51.94 ± 7.9	.844
Creatinine, mg/dL	1.3 ± 0.55	1.16 ± 0.24	1.16 ± 0.31	1.74 ± 0.89	<b>.001</b>
ECG changes, %	93.4 (n=71)	90.5 (n=19)	91.9 (n=34)	100 (n=18)	.42
Elevated troponins, %	92.1 (n=70)	85.8 (n=18)	91.9 (n=34)	100 (n=18)	.25
Killip > I, %	47.4 (n=39)	33.3 (n=7)	43.2 (n=16)	72.2 (n=13)	<b>.04</b>
3-vessel, %	68.4 (n=52)	52.4 (n=11)	92.2 (n=33)	94.4 (n=17)	<b>.001</b>
Left main, %	31.6 (n=24)	52.4 (n=11)	13.5 (n=5)	44.4 (n=8)	<b>.004</b>
bSS < 22, %	18.4 (n=14)	42.9 (n=9)	10.8 (n=4)	5.6 (n=1)	
bSS 22-32, %	38.2 (n=29)	42.9 (n=9)	48.6 (n=18)	11.1 (n=2)	<b>.001*</b>
bSS > 32, %	43.4 (n=33)	14.3 (n=3)	40.5 (n=15)	83.3 (n=15)	
No. of lesions	3.75 ± 1.5	2.7 ± 1.1	4.05 ± 1.2	4.39 ± 1.7	<b>.001</b>
DES, %	60.5 (n=46)	90.5 (n=2)	54.1 (n=20)	38.9 (n=7)	<b>.001</b>
Revascularizable, %	69.7 (n=53)	28.6 (n=6)	83.8 (n=31)	88.9 (n=16)	<b>.001</b>
GRACE mort/AMI during adm, %	34.9 ± 20.7	24.8	32.2	54.4	<b>.002</b>
GRACE mort/AMI at 6 mo, %	47.9 ± 15.7	41	46	61	<b>.001</b>
CHARLSON	2.4 ± 1.02	2.1 ± 0.8	2.4 ± 0.96	2.7 ± 1.3	.161

bSS, baseline SYNTAX score; CIHD, chronic ischemic heart disease; COPD, chronic obstructive pulmonary disease; DEL, drug-eluting stent; ECG, electrocardiogram; GRACE mort/AMI during adm and at 6 mo, risk of mortality and acute myocardial infarction, by GRACE score during admission and at 6 months; LVEF, left ventricular ejection fraction; No. of lesions, number of coronary artery lesions per patient; PVD, peripheral vascular disease; rSS, residual SYNTAX score; 3-vessel, coronary disease involving 3 vessels.

Continuous quantitative variables are expressed as mean ± standard deviation.

\* P value resulting from the overall comparison of bSS and rSS.

is a strong prognostic factor of coronary events and all-cause death in patients who have undergone PCI.<sup>3</sup>


The aim of this study was to investigate the predictive value of rSS in a sample of octogenarian patients with NSTEMI and multivessel disease.

We performed a retrospective analysis of the data of 76 consecutive patients, aged 80 years or older, admitted with NSTEMI to a tertiary referral hospital between June 2013 and June 2014, and who received invasive treatment. All patients had multivessel disease. Patients received PCI at the decision of their cardiologist, at a site that generally performs culprit-vessel PCI in high-risk patients. The primary study variable was a composite of all-cause death and myocardial infarction (5-fold increase of baseline troponin) during admission and at 6 months. We calculated the GRACE score (Global Registry of Acute Coronary Events) for death and infarction during admission and at 6 months, the baseline SYNTAX score (bSS), rSS, and the Charlson comorbidity index. As in other studies,<sup>3</sup> we grouped patients into terciles, according to their bSS and rSS (Table). Two interventional cardiologists analyzed untreated lesions and classified patients as "revascularizable" if they found any treatable lesions. We then performed a multivariable analysis with the GRACE and Charlson scores, bSS/rSS, left ventricular ejection fraction, age, creatinine, use of drug-eluting stents, and left main/3-vessel disease as variables, calculating logistic regression during admission and at follow-up.

The Table shows baseline characteristics and variables during admission, by rSS. Three-vessel disease was found in 68.4% of the

patients, and left main coronary artery disease was found in 31.6%. With regard to baseline coronary disease, 38.2% and 43.4% of patients had a bSS score of 22-32 and > 32, respectively. After PCI (with drug-eluting stents deployed in 6.5% of patients), 27.6% of patients achieved an rSS < 8, while 48.7% and 23.7% still had an rSS of 8-20 and > 20, respectively. By rSS tercile, 28.6%, 83.8%, and 88.9% of patients had potentially revascularizable lesions after PCI.

We found the composite variable was present in 34.2% of patients during admission (26 events: 4.7% with rSS < 8, 27.1% with rSS 8-20, and 83.3% with rSS > 20;  $P < .001$ ) and in 56.6% at 6 months (43 events: 14.3% with rSS < 8, 62.1% with rSS 8-20, and 94.4% with rSS > 20;  $P < .001$ ). All patients survived in the rSS < 8 tercile. During admission, 7 patients died (2 with rSS 8-20 and 5 with rSS > 20;  $P = .006$ ), and during follow up, 14 patients died (4 with rSS 8-20 and 10 with rSS > 20;  $P < .001$ ). The Figure shows the primary variable and all-cause death by rSS. In the multivariable analysis of events during admission, the following variables were significant predictors: the GRACE score [odds ratio (OR) = 1.07; 95% confidence interval (95%CI), 1.005-1.15;  $P = .036$ ; area under the curve (AUC), 0.83; 95%CI, 0.72-0.94;  $P < .001$ ], bSS (OR = 1.13; 95%CI, 1.02-1.25;  $P = .023$ ; AUC, 0.82; 95%CI, 0.70-0.94;  $P < .001$ ), and rSS (OR = 3.4; 95%CI, 1.005-12.39;  $P = .05$ ; AUC, 0.86; 95%CI, 0.76-0.96;  $P < .001$ ). At 6 months, the following variables reached statistical significance: the GRACE score (OR = 1.45; 95%CI, 0.995-2.12;  $P = .05$ ; AUC, 0.75; 95%CI, 0.62-0.86;  $P = .002$ ), bSS (OR = 1.33; 95%CI, 1.11-1.59;  $P = .002$ ; AUC, 0.87; 95%CI, 0.78-0.97;  $P < .001$ ), and rSS (OR = 9.4; 95%CI, 1.61-55.1;  $P = .013$ ; AUC, 0.86;



**Figure.** Mortality during admission and at 6 months; mortality/reinfarction during admission and at 6 months; GRACE score for mortality/infarction during admission and at 6 months, by residual SYNTAX score tertile. AMI, acute myocardial infarction; rSS, residual SYNTAX score.

95%CI, 0.76-0.96;  $P < .001$ ). The bSS and rSS were independent predictors when one or the other was removed from the analysis to avoid any colinearity between them.

Our study results confirm the relevance of the GRACE score and bSS as predictors of cardiovascular events in octogenarian patients with NSTEMI-ACS and multivessel disease and, for the first time, identify rSS as a predictive factor for these events.

Despite the existing tendency toward conservative treatment in octogenarian patients,<sup>2</sup> our results suggest that more extensive revascularization might improve the prognosis of octogenarian patients with NSTEMI-ACS. In our opinion, advanced age and frailty should not be contraindications to performing the most complete revascularization possible. Since the need for dual antiplatelet therapy is already present in culprit-vessel PCI, complete revascularization should have a limited impact on the risk, and it should enhance the benefit. Although the differences in mortality may be explained by higher (but not statistically significant) comorbidity rates in the top tertile, we believe that the cardiovascular risk inherent in untreated lesions may play an important role.

The limitations of our study stem from its retrospective design and its short 6-month follow-up. Although we were unable to control all possible confounders and had a limited sample size, the differences are of sufficient significance to suggest that rSS has a prognostic value.

In conclusion, we believe our results show that rSS is a strong predictor of cardiovascular events in octogenarian patients with NSTEMI-ACS and that more extensive revascularization might

improve the prognosis of these patients. However, randomized studies are needed to confirm this hypothesis.

Felipe Díez-Delhoyo, Fernando Sarnago Cebada,\* Luis Manuel Cressa, Allan Rivera-Juárez, Jaime Elízaga, and Francisco Fernández-Avilés

*Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Madrid, Spain*

\*Corresponding author:

*E-mail address:* [fcb2@hotmail.com](mailto:fcb2@hotmail.com) (F. Sarnago Cebada).

Available online 12 January 2016

## REFERENCES

- Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. *Rev Esp Cardiol.* 2012;65: 173.e1-e55.
- Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. *J Am Coll Cardiol.* 2010;55:2435–45.
- Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. *J Am Coll Cardiol.* 2012;59:2165–74.

<http://dx.doi.org/10.1016/j.rec.2015.09.019>